Wang H, et al. - Among 124 drug-naïve type 2 diabetics who received continuous subcutaneous insulin infusion (CSII) for 2 weeks, researchers identified predictors of 2-year glycemic remission after short-term intensive insulin treatment. In this clamp-based study, euglycemic-hyperinsulinemic clamps and intravenous glucose tolerance tests were performed to evaluate the insulin sensitivity (glucose infusion rate) and acute insulin response pre- and post-CSII. After 12 and 24 months of follow-up, glycemic remission rates were 47.6% and 30.7%, respectively. According to findings, younger age at diabetes diagnosis, higher baseline insulin sensitivity, and lower glucose levels after insulin treatment significantly favored a 2-year glycemic remission. The investigators observed that this long-term remission was due to both improved insulin sensitivity and improved β-cell function following short-term intensive insulin treatment.